These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33117686)

  • 1. Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.
    Luo Y; Jiang H; Xu W; Wang X; Ma B; Liao T; Wang Y
    Front Oncol; 2020; 10():549882. PubMed ID: 33117686
    [No Abstract]   [Full Text] [Related]  

  • 2. Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.
    Yang J; Gong Y; Yan S; Chen H; Qin S; Gong R
    Endocrine; 2020 Jan; 67(1):44-57. PubMed ID: 31655978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
    Zhang Q; Liu SZ; Zhang Q; Guan YX; Chen QJ; Zhu QY
    Cell Physiol Biochem; 2016; 38(2):763-76. PubMed ID: 26871894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
    Liu W; Jiang B; Xue J; Liu R; Wei Y; Li P
    Ann Diagn Pathol; 2024 Apr; 69():152243. PubMed ID: 38128440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Coexistent BRAF
    Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
    Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis.
    Su X; Jiang X; Wang W; Wang H; Xu X; Lin A; Teng X; Wu H; Teng L
    Onco Targets Ther; 2016; 9():6965-6976. PubMed ID: 27956840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
    Maghsoomi Z; Emami Z; Malboosbaf R; Malek M; Khamseh ME
    BMC Cancer; 2021 May; 21(1):579. PubMed ID: 34016077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis.
    Yin DT; Yu K; Lu RQ; Li X; Xu J; Lei M; Li H; Wang Y; Liu Z
    Clin Endocrinol (Oxf); 2016 Aug; 85(2):299-305. PubMed ID: 26732020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis.
    Wang Z; Chen JQ; Liu JL; Qin XG
    Eur J Clin Invest; 2016 Feb; 46(2):146-57. PubMed ID: 26648183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Papillary thyroid carcinoma with tall cell features is as aggressive as tall cell variant: a meta-analysis.
    Vuong HG; Long NP; Anh NH; Nghi TD; Hieu MV; Hung LP; Nakazawa T; Katoh R; Kondo T
    Endocr Connect; 2018 Dec; 7(12):R286-R293. PubMed ID: 30352403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
    Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y
    J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
    Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
    Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Value of BRAF
    Song JY; Sun SR; Dong F; Huang T; Wu B; Zhou J
    Curr Med Sci; 2018 Oct; 38(5):785-797. PubMed ID: 30341513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis.
    Ma YJ; Deng XL; Li HQ
    J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):591-599. PubMed ID: 26223933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis.
    Feng G; Luo Y; Zhang Q; Zeng F; Xu J; Zhu J
    Endocrine; 2020 Apr; 68(1):56-63. PubMed ID: 31955344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
    Kim TH; Park YJ; Lim JA; Ahn HY; Lee EK; Lee YJ; Kim KW; Hahn SK; Youn YK; Kim KH; Cho BY; Park DJ
    Cancer; 2012 Apr; 118(7):1764-73. PubMed ID: 21882184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M; Yan C; Xiao J; Wang T; Ling R
    Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological Risk Factors for Distant Metastasis in Differentiated Thyroid Carcinoma: A Meta-analysis.
    Vuong HG; Duong UNP; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
    World J Surg; 2018 Apr; 42(4):1005-1017. PubMed ID: 28913696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region.
    Passler C; Scheuba C; Prager G; Kaczirek K; Kaserer K; Zettinig G; Niederle B
    Endocr Relat Cancer; 2004 Mar; 11(1):131-9. PubMed ID: 15027890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
    Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
    Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.